cryopreservation system Search Results


acs 6000  (ATCC)
90
ATCC acs 6000
Acs 6000, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/acs 6000/product/ATCC
Average 90 stars, based on 1 article reviews
acs 6000 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cell culture primary human white preadipocytes  (PromoCell)
94
PromoCell cell culture primary human white preadipocytes
Cell Culture Primary Human White Preadipocytes, supplied by PromoCell, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cell culture primary human white preadipocytes/product/PromoCell
Average 94 stars, based on 1 article reviews
cell culture primary human white preadipocytes - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
pbmcs cryopreserved human peripheral blood mononuclear cells pbmcs  (ZenBio)
93
ZenBio pbmcs cryopreserved human peripheral blood mononuclear cells pbmcs
Pbmcs Cryopreserved Human Peripheral Blood Mononuclear Cells Pbmcs, supplied by ZenBio, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pbmcs cryopreserved human peripheral blood mononuclear cells pbmcs/product/ZenBio
Average 93 stars, based on 1 article reviews
pbmcs cryopreserved human peripheral blood mononuclear cells pbmcs - by Bioz Stars, 2026-03
93/100 stars
  Buy from Supplier
cryopreservation medium  (GE Healthcare)
91
GE Healthcare cryopreservation medium
Cryopreservation Medium, supplied by GE Healthcare, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cryopreservation medium/product/GE Healthcare
Average 91 stars, based on 1 article reviews
cryopreservation medium - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier
peripheral blood cd34 cells  (AMS Biotechnology)
96
AMS Biotechnology peripheral blood cd34 cells
Pharmaceutical inhibition of RAS signaling is unaffected by cytokine treatment (A) Chemical structures of RAS small molecule inhibitors. (B) Western blot of extracts from MOLM14 cells treated with 10 nM Gilteritinib or 15 μM Ch-3 in the presence and absence of 10 ng/mL IL-3. A representative western blot and densitometry of signals from phospho-ERK, ERK and GAPDH are shown (n = 3), error bars show standard deviation, p values of significance vs. the untreated sample were calculated using Student’s t test are shown in the table. (C and D) Dose-response curve depicting the viability of MV4-11 cells (C) and ITD18 primary cells (D) treated with Ch-3 cultured in the presence of various mixtures of cytokines at 10 ng/mL. Tables of IC50 ± standard deviation (n = 3) are shown in bottom panels. (E) Dose-response curves depicting the viability of primary cells ITD18 and ITD16 relapse sample after FLT3i treated with RAS inhibitors in cultures with low, high or high+IL-3 concentrations. The table of IC50s ± standard deviation (n = 3) is included in the bottom panel. (F) Dose-response curves depicting the viability of FLT3-ITD+ AML (ITD19), FLT3 WT AML and heathy <t>CD34</t> + cells treated with Ch-3. The table of IC50 ± standard deviation (n = 3) is shown. (G) Histogram of EDU+ cells from the ITD16_G (n = 3) and ITD18 (n = 2) LSC or Blast populations treated with Gilteritinib or Ch-3 in the presence or absence of 100 ng/mL IL-3. Significant differences are indicated by p values calculated using Student’s t test comparing populations treated with and without IL-3, error bars show standard deviation. (H) Relative signal of phosphorylated signaling proteins detected by CYTOF in ITD18 cells treated with 100 nM Gilteritinib or 20 μM Ch-3 in the presence or absence of 100 ng/mL IL-3. All IC50 values show the mean IC50 ± standard deviation (n = 3).
Peripheral Blood Cd34 Cells, supplied by AMS Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/peripheral blood cd34 cells/product/AMS Biotechnology
Average 96 stars, based on 1 article reviews
peripheral blood cd34 cells - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
peripheral blood mononuclear cells pbmcs  (AMS Biotechnology)
96
AMS Biotechnology peripheral blood mononuclear cells pbmcs
Pharmaceutical inhibition of RAS signaling is unaffected by cytokine treatment (A) Chemical structures of RAS small molecule inhibitors. (B) Western blot of extracts from MOLM14 cells treated with 10 nM Gilteritinib or 15 μM Ch-3 in the presence and absence of 10 ng/mL IL-3. A representative western blot and densitometry of signals from phospho-ERK, ERK and GAPDH are shown (n = 3), error bars show standard deviation, p values of significance vs. the untreated sample were calculated using Student’s t test are shown in the table. (C and D) Dose-response curve depicting the viability of MV4-11 cells (C) and ITD18 primary cells (D) treated with Ch-3 cultured in the presence of various mixtures of cytokines at 10 ng/mL. Tables of IC50 ± standard deviation (n = 3) are shown in bottom panels. (E) Dose-response curves depicting the viability of primary cells ITD18 and ITD16 relapse sample after FLT3i treated with RAS inhibitors in cultures with low, high or high+IL-3 concentrations. The table of IC50s ± standard deviation (n = 3) is included in the bottom panel. (F) Dose-response curves depicting the viability of FLT3-ITD+ AML (ITD19), FLT3 WT AML and heathy <t>CD34</t> + cells treated with Ch-3. The table of IC50 ± standard deviation (n = 3) is shown. (G) Histogram of EDU+ cells from the ITD16_G (n = 3) and ITD18 (n = 2) LSC or Blast populations treated with Gilteritinib or Ch-3 in the presence or absence of 100 ng/mL IL-3. Significant differences are indicated by p values calculated using Student’s t test comparing populations treated with and without IL-3, error bars show standard deviation. (H) Relative signal of phosphorylated signaling proteins detected by CYTOF in ITD18 cells treated with 100 nM Gilteritinib or 20 μM Ch-3 in the presence or absence of 100 ng/mL IL-3. All IC50 values show the mean IC50 ± standard deviation (n = 3).
Peripheral Blood Mononuclear Cells Pbmcs, supplied by AMS Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/peripheral blood mononuclear cells pbmcs/product/AMS Biotechnology
Average 96 stars, based on 1 article reviews
peripheral blood mononuclear cells pbmcs - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
sk120211 amsbio cat  (AMS Biotechnology)
96
AMS Biotechnology sk120211 amsbio cat
Pharmaceutical inhibition of RAS signaling is unaffected by cytokine treatment (A) Chemical structures of RAS small molecule inhibitors. (B) Western blot of extracts from MOLM14 cells treated with 10 nM Gilteritinib or 15 μM Ch-3 in the presence and absence of 10 ng/mL IL-3. A representative western blot and densitometry of signals from phospho-ERK, ERK and GAPDH are shown (n = 3), error bars show standard deviation, p values of significance vs. the untreated sample were calculated using Student’s t test are shown in the table. (C and D) Dose-response curve depicting the viability of MV4-11 cells (C) and ITD18 primary cells (D) treated with Ch-3 cultured in the presence of various mixtures of cytokines at 10 ng/mL. Tables of IC50 ± standard deviation (n = 3) are shown in bottom panels. (E) Dose-response curves depicting the viability of primary cells ITD18 and ITD16 relapse sample after FLT3i treated with RAS inhibitors in cultures with low, high or high+IL-3 concentrations. The table of IC50s ± standard deviation (n = 3) is included in the bottom panel. (F) Dose-response curves depicting the viability of FLT3-ITD+ AML (ITD19), FLT3 WT AML and heathy <t>CD34</t> + cells treated with Ch-3. The table of IC50 ± standard deviation (n = 3) is shown. (G) Histogram of EDU+ cells from the ITD16_G (n = 3) and ITD18 (n = 2) LSC or Blast populations treated with Gilteritinib or Ch-3 in the presence or absence of 100 ng/mL IL-3. Significant differences are indicated by p values calculated using Student’s t test comparing populations treated with and without IL-3, error bars show standard deviation. (H) Relative signal of phosphorylated signaling proteins detected by CYTOF in ITD18 cells treated with 100 nM Gilteritinib or 20 μM Ch-3 in the presence or absence of 100 ng/mL IL-3. All IC50 values show the mean IC50 ± standard deviation (n = 3).
Sk120211 Amsbio Cat, supplied by AMS Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sk120211 amsbio cat/product/AMS Biotechnology
Average 96 stars, based on 1 article reviews
sk120211 amsbio cat - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
cryopreservation solution cellbanker 1  (Zenyaku Kogyo Co Ltd)
94
Zenyaku Kogyo Co Ltd cryopreservation solution cellbanker 1
Pharmaceutical inhibition of RAS signaling is unaffected by cytokine treatment (A) Chemical structures of RAS small molecule inhibitors. (B) Western blot of extracts from MOLM14 cells treated with 10 nM Gilteritinib or 15 μM Ch-3 in the presence and absence of 10 ng/mL IL-3. A representative western blot and densitometry of signals from phospho-ERK, ERK and GAPDH are shown (n = 3), error bars show standard deviation, p values of significance vs. the untreated sample were calculated using Student’s t test are shown in the table. (C and D) Dose-response curve depicting the viability of MV4-11 cells (C) and ITD18 primary cells (D) treated with Ch-3 cultured in the presence of various mixtures of cytokines at 10 ng/mL. Tables of IC50 ± standard deviation (n = 3) are shown in bottom panels. (E) Dose-response curves depicting the viability of primary cells ITD18 and ITD16 relapse sample after FLT3i treated with RAS inhibitors in cultures with low, high or high+IL-3 concentrations. The table of IC50s ± standard deviation (n = 3) is included in the bottom panel. (F) Dose-response curves depicting the viability of FLT3-ITD+ AML (ITD19), FLT3 WT AML and heathy <t>CD34</t> + cells treated with Ch-3. The table of IC50 ± standard deviation (n = 3) is shown. (G) Histogram of EDU+ cells from the ITD16_G (n = 3) and ITD18 (n = 2) LSC or Blast populations treated with Gilteritinib or Ch-3 in the presence or absence of 100 ng/mL IL-3. Significant differences are indicated by p values calculated using Student’s t test comparing populations treated with and without IL-3, error bars show standard deviation. (H) Relative signal of phosphorylated signaling proteins detected by CYTOF in ITD18 cells treated with 100 nM Gilteritinib or 20 μM Ch-3 in the presence or absence of 100 ng/mL IL-3. All IC50 values show the mean IC50 ± standard deviation (n = 3).
Cryopreservation Solution Cellbanker 1, supplied by Zenyaku Kogyo Co Ltd, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cryopreservation solution cellbanker 1/product/Zenyaku Kogyo Co Ltd
Average 94 stars, based on 1 article reviews
cryopreservation solution cellbanker 1 - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
organoid cryopreservation medium biogenous cat  (MedChemExpress)
94
MedChemExpress organoid cryopreservation medium biogenous cat
Pharmaceutical inhibition of RAS signaling is unaffected by cytokine treatment (A) Chemical structures of RAS small molecule inhibitors. (B) Western blot of extracts from MOLM14 cells treated with 10 nM Gilteritinib or 15 μM Ch-3 in the presence and absence of 10 ng/mL IL-3. A representative western blot and densitometry of signals from phospho-ERK, ERK and GAPDH are shown (n = 3), error bars show standard deviation, p values of significance vs. the untreated sample were calculated using Student’s t test are shown in the table. (C and D) Dose-response curve depicting the viability of MV4-11 cells (C) and ITD18 primary cells (D) treated with Ch-3 cultured in the presence of various mixtures of cytokines at 10 ng/mL. Tables of IC50 ± standard deviation (n = 3) are shown in bottom panels. (E) Dose-response curves depicting the viability of primary cells ITD18 and ITD16 relapse sample after FLT3i treated with RAS inhibitors in cultures with low, high or high+IL-3 concentrations. The table of IC50s ± standard deviation (n = 3) is included in the bottom panel. (F) Dose-response curves depicting the viability of FLT3-ITD+ AML (ITD19), FLT3 WT AML and heathy <t>CD34</t> + cells treated with Ch-3. The table of IC50 ± standard deviation (n = 3) is shown. (G) Histogram of EDU+ cells from the ITD16_G (n = 3) and ITD18 (n = 2) LSC or Blast populations treated with Gilteritinib or Ch-3 in the presence or absence of 100 ng/mL IL-3. Significant differences are indicated by p values calculated using Student’s t test comparing populations treated with and without IL-3, error bars show standard deviation. (H) Relative signal of phosphorylated signaling proteins detected by CYTOF in ITD18 cells treated with 100 nM Gilteritinib or 20 μM Ch-3 in the presence or absence of 100 ng/mL IL-3. All IC50 values show the mean IC50 ± standard deviation (n = 3).
Organoid Cryopreservation Medium Biogenous Cat, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/organoid cryopreservation medium biogenous cat/product/MedChemExpress
Average 94 stars, based on 1 article reviews
organoid cryopreservation medium biogenous cat - by Bioz Stars, 2026-03
94/100 stars
  Buy from Supplier
human induced pluripotent stem cell ipsc derived microglia img  (Axol Bioscience)
90
Axol Bioscience human induced pluripotent stem cell ipsc derived microglia img
Pharmaceutical inhibition of RAS signaling is unaffected by cytokine treatment (A) Chemical structures of RAS small molecule inhibitors. (B) Western blot of extracts from MOLM14 cells treated with 10 nM Gilteritinib or 15 μM Ch-3 in the presence and absence of 10 ng/mL IL-3. A representative western blot and densitometry of signals from phospho-ERK, ERK and GAPDH are shown (n = 3), error bars show standard deviation, p values of significance vs. the untreated sample were calculated using Student’s t test are shown in the table. (C and D) Dose-response curve depicting the viability of MV4-11 cells (C) and ITD18 primary cells (D) treated with Ch-3 cultured in the presence of various mixtures of cytokines at 10 ng/mL. Tables of IC50 ± standard deviation (n = 3) are shown in bottom panels. (E) Dose-response curves depicting the viability of primary cells ITD18 and ITD16 relapse sample after FLT3i treated with RAS inhibitors in cultures with low, high or high+IL-3 concentrations. The table of IC50s ± standard deviation (n = 3) is included in the bottom panel. (F) Dose-response curves depicting the viability of FLT3-ITD+ AML (ITD19), FLT3 WT AML and heathy <t>CD34</t> + cells treated with Ch-3. The table of IC50 ± standard deviation (n = 3) is shown. (G) Histogram of EDU+ cells from the ITD16_G (n = 3) and ITD18 (n = 2) LSC or Blast populations treated with Gilteritinib or Ch-3 in the presence or absence of 100 ng/mL IL-3. Significant differences are indicated by p values calculated using Student’s t test comparing populations treated with and without IL-3, error bars show standard deviation. (H) Relative signal of phosphorylated signaling proteins detected by CYTOF in ITD18 cells treated with 100 nM Gilteritinib or 20 μM Ch-3 in the presence or absence of 100 ng/mL IL-3. All IC50 values show the mean IC50 ± standard deviation (n = 3).
Human Induced Pluripotent Stem Cell Ipsc Derived Microglia Img, supplied by Axol Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human induced pluripotent stem cell ipsc derived microglia img/product/Axol Bioscience
Average 90 stars, based on 1 article reviews
human induced pluripotent stem cell ipsc derived microglia img - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
dmso  (Bio-Techne corporation)
90
Bio-Techne corporation dmso
Pharmaceutical inhibition of RAS signaling is unaffected by cytokine treatment (A) Chemical structures of RAS small molecule inhibitors. (B) Western blot of extracts from MOLM14 cells treated with 10 nM Gilteritinib or 15 μM Ch-3 in the presence and absence of 10 ng/mL IL-3. A representative western blot and densitometry of signals from phospho-ERK, ERK and GAPDH are shown (n = 3), error bars show standard deviation, p values of significance vs. the untreated sample were calculated using Student’s t test are shown in the table. (C and D) Dose-response curve depicting the viability of MV4-11 cells (C) and ITD18 primary cells (D) treated with Ch-3 cultured in the presence of various mixtures of cytokines at 10 ng/mL. Tables of IC50 ± standard deviation (n = 3) are shown in bottom panels. (E) Dose-response curves depicting the viability of primary cells ITD18 and ITD16 relapse sample after FLT3i treated with RAS inhibitors in cultures with low, high or high+IL-3 concentrations. The table of IC50s ± standard deviation (n = 3) is included in the bottom panel. (F) Dose-response curves depicting the viability of FLT3-ITD+ AML (ITD19), FLT3 WT AML and heathy <t>CD34</t> + cells treated with Ch-3. The table of IC50 ± standard deviation (n = 3) is shown. (G) Histogram of EDU+ cells from the ITD16_G (n = 3) and ITD18 (n = 2) LSC or Blast populations treated with Gilteritinib or Ch-3 in the presence or absence of 100 ng/mL IL-3. Significant differences are indicated by p values calculated using Student’s t test comparing populations treated with and without IL-3, error bars show standard deviation. (H) Relative signal of phosphorylated signaling proteins detected by CYTOF in ITD18 cells treated with 100 nM Gilteritinib or 20 μM Ch-3 in the presence or absence of 100 ng/mL IL-3. All IC50 values show the mean IC50 ± standard deviation (n = 3).
Dmso, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dmso/product/Bio-Techne corporation
Average 90 stars, based on 1 article reviews
dmso - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cryopreservation medium  (ZenBio)
91
ZenBio cryopreservation medium
Pharmaceutical inhibition of RAS signaling is unaffected by cytokine treatment (A) Chemical structures of RAS small molecule inhibitors. (B) Western blot of extracts from MOLM14 cells treated with 10 nM Gilteritinib or 15 μM Ch-3 in the presence and absence of 10 ng/mL IL-3. A representative western blot and densitometry of signals from phospho-ERK, ERK and GAPDH are shown (n = 3), error bars show standard deviation, p values of significance vs. the untreated sample were calculated using Student’s t test are shown in the table. (C and D) Dose-response curve depicting the viability of MV4-11 cells (C) and ITD18 primary cells (D) treated with Ch-3 cultured in the presence of various mixtures of cytokines at 10 ng/mL. Tables of IC50 ± standard deviation (n = 3) are shown in bottom panels. (E) Dose-response curves depicting the viability of primary cells ITD18 and ITD16 relapse sample after FLT3i treated with RAS inhibitors in cultures with low, high or high+IL-3 concentrations. The table of IC50s ± standard deviation (n = 3) is included in the bottom panel. (F) Dose-response curves depicting the viability of FLT3-ITD+ AML (ITD19), FLT3 WT AML and heathy <t>CD34</t> + cells treated with Ch-3. The table of IC50 ± standard deviation (n = 3) is shown. (G) Histogram of EDU+ cells from the ITD16_G (n = 3) and ITD18 (n = 2) LSC or Blast populations treated with Gilteritinib or Ch-3 in the presence or absence of 100 ng/mL IL-3. Significant differences are indicated by p values calculated using Student’s t test comparing populations treated with and without IL-3, error bars show standard deviation. (H) Relative signal of phosphorylated signaling proteins detected by CYTOF in ITD18 cells treated with 100 nM Gilteritinib or 20 μM Ch-3 in the presence or absence of 100 ng/mL IL-3. All IC50 values show the mean IC50 ± standard deviation (n = 3).
Cryopreservation Medium, supplied by ZenBio, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cryopreservation medium/product/ZenBio
Average 91 stars, based on 1 article reviews
cryopreservation medium - by Bioz Stars, 2026-03
91/100 stars
  Buy from Supplier

Image Search Results


Pharmaceutical inhibition of RAS signaling is unaffected by cytokine treatment (A) Chemical structures of RAS small molecule inhibitors. (B) Western blot of extracts from MOLM14 cells treated with 10 nM Gilteritinib or 15 μM Ch-3 in the presence and absence of 10 ng/mL IL-3. A representative western blot and densitometry of signals from phospho-ERK, ERK and GAPDH are shown (n = 3), error bars show standard deviation, p values of significance vs. the untreated sample were calculated using Student’s t test are shown in the table. (C and D) Dose-response curve depicting the viability of MV4-11 cells (C) and ITD18 primary cells (D) treated with Ch-3 cultured in the presence of various mixtures of cytokines at 10 ng/mL. Tables of IC50 ± standard deviation (n = 3) are shown in bottom panels. (E) Dose-response curves depicting the viability of primary cells ITD18 and ITD16 relapse sample after FLT3i treated with RAS inhibitors in cultures with low, high or high+IL-3 concentrations. The table of IC50s ± standard deviation (n = 3) is included in the bottom panel. (F) Dose-response curves depicting the viability of FLT3-ITD+ AML (ITD19), FLT3 WT AML and heathy CD34 + cells treated with Ch-3. The table of IC50 ± standard deviation (n = 3) is shown. (G) Histogram of EDU+ cells from the ITD16_G (n = 3) and ITD18 (n = 2) LSC or Blast populations treated with Gilteritinib or Ch-3 in the presence or absence of 100 ng/mL IL-3. Significant differences are indicated by p values calculated using Student’s t test comparing populations treated with and without IL-3, error bars show standard deviation. (H) Relative signal of phosphorylated signaling proteins detected by CYTOF in ITD18 cells treated with 100 nM Gilteritinib or 20 μM Ch-3 in the presence or absence of 100 ng/mL IL-3. All IC50 values show the mean IC50 ± standard deviation (n = 3).

Journal: iScience

Article Title: Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1

doi: 10.1016/j.isci.2024.109576

Figure Lengend Snippet: Pharmaceutical inhibition of RAS signaling is unaffected by cytokine treatment (A) Chemical structures of RAS small molecule inhibitors. (B) Western blot of extracts from MOLM14 cells treated with 10 nM Gilteritinib or 15 μM Ch-3 in the presence and absence of 10 ng/mL IL-3. A representative western blot and densitometry of signals from phospho-ERK, ERK and GAPDH are shown (n = 3), error bars show standard deviation, p values of significance vs. the untreated sample were calculated using Student’s t test are shown in the table. (C and D) Dose-response curve depicting the viability of MV4-11 cells (C) and ITD18 primary cells (D) treated with Ch-3 cultured in the presence of various mixtures of cytokines at 10 ng/mL. Tables of IC50 ± standard deviation (n = 3) are shown in bottom panels. (E) Dose-response curves depicting the viability of primary cells ITD18 and ITD16 relapse sample after FLT3i treated with RAS inhibitors in cultures with low, high or high+IL-3 concentrations. The table of IC50s ± standard deviation (n = 3) is included in the bottom panel. (F) Dose-response curves depicting the viability of FLT3-ITD+ AML (ITD19), FLT3 WT AML and heathy CD34 + cells treated with Ch-3. The table of IC50 ± standard deviation (n = 3) is shown. (G) Histogram of EDU+ cells from the ITD16_G (n = 3) and ITD18 (n = 2) LSC or Blast populations treated with Gilteritinib or Ch-3 in the presence or absence of 100 ng/mL IL-3. Significant differences are indicated by p values calculated using Student’s t test comparing populations treated with and without IL-3, error bars show standard deviation. (H) Relative signal of phosphorylated signaling proteins detected by CYTOF in ITD18 cells treated with 100 nM Gilteritinib or 20 μM Ch-3 in the presence or absence of 100 ng/mL IL-3. All IC50 values show the mean IC50 ± standard deviation (n = 3).

Article Snippet: Human Mobilized Peripheral Blood CD34 + Cells, used as healthy controls, were purchased from AMS Biotechnology (Europe) Limited.

Techniques: Inhibition, Western Blot, Standard Deviation, Cell Culture

Journal: iScience

Article Title: Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1

doi: 10.1016/j.isci.2024.109576

Figure Lengend Snippet:

Article Snippet: Human Mobilized Peripheral Blood CD34 + Cells, used as healthy controls, were purchased from AMS Biotechnology (Europe) Limited.

Techniques: Control, Virus, Recombinant, Modification, Saline, Stripping Membranes, Protease Inhibitor, Reverse Transcription, Membrane, Labeling, Gel Extraction, Plasmid Preparation, Software